Vortioxetine

Synopsis, Chemistry

APIs // Active Pharmaceutical Ingredients

44 Suppliers, 22 USDMF, 3 JDMF, 5 EU WC, 8 KDMF, 8 NDC API, 31 Listed Suppliers

DEVELOPMENTS

4 Drug(s) in Development

4 Drug(s) in Development

PRICE INFORMATION

API Reference Price, API Exports, API Imports

INTERMEDIATES

9 Suppliers

9 Suppliers

DOSSIERs // Finished Dosage Forms

62 Dossiers, 18 FDA Orange Book, 19 Europe, 3 Canada, 9 South Africa, 13 Listed Dossiers

DRUG PRODUCT COMPOSITION

TABLET;ORAL - EQ 10MG BASE, TABLET;ORAL - EQ 15MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET;ORAL - EQ 20MG BASE, TABLET;ORAL - EQ 5MG BASE

RELATED EXCIPIENT COMPANIES

Suppliers, 14 Roquette, 13 SPI Pharma, 9 Sigachi Industries, 9 Microlex e.U, 8 Gangwal Healthcare, 5 Kerry, 4 Gangwal Chemicals, 3 Vasa Pharmachem, 3 Shanghai Shenmei Pharmaceutical Technology Co., Ltd, 3 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd, 3 Prachin Chemical, 3 DFE Pharma, 2 Ingredion Pharma Solutions, 2 Pharmatrans-Sanaq, 1 DKSH, 1 Rochem International Inc, 1 Shijiazhuang Huaxu Pharmaceutical, 1 Clariant, 1 BASF, 1 Nanjing Well Pharmaceutical, 1 Pfanstiehl, 1 Ideal Cures Pvt Ltd

EXCIPIENTS BY APPLICATIONS

36 Fillers, Diluents & Binders, 20 Direct Compression, 15 Disintegrants & Superdisintegrants, 12 Thickeners and Stabilizers, 11 Lubricants & Glidants, 11 Chewable & Orodispersible Aids, 11 Taste Masking, 10 Co-Processed Excipients, 9 Granulation, 6 Coating Systems & Additives, 4 Controlled & Modified Release, 4 Parenteral, 4 Film Formers & Plasticizers, 2 Rheology Modifiers, 2 Topical, 1 Emulsifying Agents, 1 API Stability Enhancers, 1 Surfactant & Foaming Agents

GLOBAL SALES INFORMATION

8 US Medicaid Prescriptions, 14 Finished Drug Prices

MARKET PLACE

7 APIs, 3 DOSSIERS // FDF, 1 Intermediates

PATENTS

80 US Patents, 12 US Exclusivities, 12 Health Canada Patents

ANALYTICAL SOLUTION(s)

6 Other Ref. Standards

6 Other Ref. Standards

DIGITAL CONTENT

4 Data Compilation & Company Tracker #PharmaFlow, 44 News

Information, Expiry, & Status of FDA Orange Book Exclusivities covering Vortioxetine

Vortioxetine

Synopsis

Chemistry

APIs // Active Pharmaceutical Ingredients

44 Suppliers

22 USDMF

3 JDMF

5 EU WC

8 KDMF

8 NDC API

31 Listed Suppliers

DEVELOPMENTS

4 Drug(s) in Development

PRICE INFORMATION

API Reference Price

API Exports

API Imports

INTERMEDIATES

9 Suppliers

DOSSIERs // Finished Dosage Forms

62 Dossiers

18 FDA Orange Book

19 Europe

3 Canada

9 South Africa

13 Listed Dossiers

DRUG PRODUCT COMPOSITION

TABLET;ORAL - EQ 10MG BASE

TABLET;ORAL - EQ 15MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

TABLET;ORAL - EQ 20MG BASE

TABLET;ORAL - EQ 5MG BASE

RELATED EXCIPIENT COMPANIES

Suppliers

14 Roquette

13 SPI Pharma

9 Sigachi Industries

9 Microlex e.U

8 Gangwal Healthcare

5 Kerry

4 Gangwal Chemicals

3 Vasa Pharmachem

3 Shanghai Shenmei Pharmaceutical Technology Co., Ltd

3 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd

3 Prachin Chemical

3 DFE Pharma

2 Ingredion Pharma Solutions

2 Pharmatrans-Sanaq

1 DKSH

1 Rochem International Inc

1 Shijiazhuang Huaxu Pharmaceutical

1 Clariant

1 BASF

1 Nanjing Well Pharmaceutical

1 Pfanstiehl

1 Ideal Cures Pvt Ltd

EXCIPIENTS BY APPLICATIONS

36 Fillers, Diluents & Binders

20 Direct Compression

15 Disintegrants & Superdisintegrants

12 Thickeners and Stabilizers

11 Lubricants & Glidants

11 Chewable & Orodispersible Aids

11 Taste Masking

10 Co-Processed Excipients

9 Granulation

6 Coating Systems & Additives

4 Controlled & Modified Release

4 Parenteral

4 Film Formers & Plasticizers

2 Rheology Modifiers

2 Topical

1 Emulsifying Agents

1 API Stability Enhancers

1 Surfactant & Foaming Agents

GLOBAL SALES INFORMATION

8 US Medicaid Prescriptions

14 Finished Drug Prices

MARKET PLACE

7 APIs

TABLET;ORAL - EQ 15MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons